Albireo Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases in addition to other liver and gastrointestinal (GI) diseases. The initial target indication for the Company’s lead product candidate, odevixibat (formerly known as A4250), is progressive familial intrahepatic cholestasis (PFIC) Type 1 and 2, which is a rare, life-threatening genetic disorder affecting young children. The Company’s second clinical candidate is elobixibat (an IBAT inhibitor), which is approved in Japan for the treatment of chronic constipation (CIC).